TOTALLY IMPLANTABLE ARTIFICIAL LUNG

介绍了一种完全可植入的胸膜内人工肺。这个 AL旨在完全支持需要长期治疗的成年人类患者 (一个月以上)所需的人工气体交换支持 治疗和康复。该装置还将提供一座通往肺部的桥梁 当肺部恢复不可能时进行移植。AL的设计目的是 在放置装置的同时，完全由右心室灌流 与天然肺串联或并联(即，肺动脉(PA)) 至PA，或PA至左心房。MC3已经制作了几个极低的原型 阻力，高效人工肺，并与 密歇根大学已经成功地在5到5个月内植入了10个设备 8小时急性绵羊实验。在这些实验中，AL有能力 完全支持成年绵羊，同时血压下降 该装置可被右心室耐受。我们在第一阶段的目标 将对这一设计进行进一步研究，并充分描述 硅胶制成的装置的血流动力学和气体交换 膜和包覆微孔中空纤维。这一特征将 有助于确定各种设计参数如何影响 血液流动和气体交换的阻力。根据这些结果，我们将 改进设计，以长期使用为目标推进我们的研究。 拟议的商业应用：该设备的商业潜力 是广泛的。潜在的肺移植候选桥梁的数量 在美国，目前超过1,000个，其中50%被拒绝，因为 缺乏可用的供体肺，感染性并发症，以及简单的 因为他们不能忍受手术，从而使他们 对于非常珍贵的器官来说风险太高了。此外，该设备可以 适用于非终末期呼吸衰竭患者 肺移植的合适人选和接受肺移植的患者 移植失败。

A totally implantable intrapleural artificial lung (AL) is presented. The AL is designed to fully support adult human patients who require long term (more than one month) artificial gas exchange support necessary for treatment and recovery. The device will also provide a bridge to lung transplantation when lung recovery is impossible. The AL is designed to be perfused entirely by the right ventricle while the device is placed in series or in parallel with the native lungs (i.e., pulmonary artery (PA) to PA, or PA to left atrium. MC3 has prototyped several extremely low resistance, highly efficient artificial lungs, and in collaboration with the University of Michigan, has successfully implanted ten devices in 5 to 8 hour acute sheep experiments. In these experiments the AL was capable of fully supporting adult sheep while the blood pressure drop across the device was tolerable by the right ventricle. Our objective in Phase I will be to further research this design and to fully characterize the hemodynamics and gas exchange of devices that are made from silicone membrane and coated microporous hollow fibers. This characterization will be helpful in determining how the various design parameters affect resistance to blood flow and gas exchange. Based on these results we will improve the design to advance our studies aimed at long term use. PROPOSED COMMERCIAL APPLICATION: The commercial potential for this device is extensive. The number of potential bridge to lung transplant candidates in the US is currently over 1,000 of which 50% are rejected because of scarcity of available donor lungs, infectious complications, and simply because they cannot tolerate the surgical procedure thereby making them too high of a risk for very precious organs. Additionally this device may be used in patients with end stage respiratory failure who are not suitable candidates for lung transplant and patients who undergo lung transplantation failure.